US Pharma MarketingLycia raises $75M for food allergy and Graves’ disease
Lycia Therapeutics raises $75M Series D to advance protein degradation candidates for food allergy and Graves Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing…
Bay Area biotech Lycia Therapeutics is refueling with $75 million for its protein degradation platform co-founded by Nobel laureate Carolyn Bertozzi.
The company snagged the Series D from large investors such as Janus Henderson, Balyasny ...
Source: Endpoints News